arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Corbus Pharmaceuticals Holdings, Inc.

CRBP
$7.46 ▼ -0.29 (-3.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Corbus Pharmaceuticals Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $99.3M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -45.7% ↘
FCF / Share $-4.84 ↘
Trailing P/E —
Price / Book 0.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 24, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-78.54M
↓ -95.3% —
FCF / Share Free cash flow per share
$-4.84
↓ -26.5% —
Long-Term Debt Long-term obligations
$17.89M
↓ -17.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
16
Cash Quality ↓
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 14 years · 54 quarters